A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy (NCT06793709)
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Observational
Phase not listed
#Eisai Trial Site 1
Sponsor: Eisai
Last Updated: February 27, 2026
Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.
The primary purpose of this study is to investigate the safety of Tasfygo.
1. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.
Exclusion Criteria
Not applicable.
Do you think this trial is incorrectly appearing?
Design Details
AllocationN/A
Intervention ModelN/A
MaskingN/A
Number to Enroll60
Arms & Interventions
Arms
Interventions
Type: N/A
Description:
Interventions:
No Intervention
Outcome Measures
Primary Outcome Measures
Number of Participants With Adverse Drug ReactionsUp to 1 year
Secondary Outcome Measures
Percentage of Participants With Best Overall Response (BOR) Based on Physician's AssessmentUp to 1 year